NCT01502982 - Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2014

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

R-CHOEP14x6+HD-AraC+HD-Mtx

rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h

Trial Locations (4)

Unknown

Odense University Hospital, Odense

Helsinki University central Hospital, Helsinki

Oslo University Hospital, Oslo

Lund University Hospital, Lund